Neurosurgery Watch

Stay up to date with the latest clinical findings in Neurosurgery Watch. Each month, our panel identifies and summarizes key points of selected significant papers from over 50 journals. We emphasize the most significant findings that potentially change clinical management or treatment of neurological diseases.

Please contact us with any suggestions or comments.

John S. Kuo, MD PhD FACS
Austin, Texas
Co-Editor
Robert Starke, MD MSc
Miami, Florida 
Co-Editor
Search Neurosurgery Watch

Public Reporting of Surgical Outcomes: Position Statement and Recommendations

February 28, 2014
By: 
Nader Pouratian, MD PhD
Source: 
Surgical Quality Alliance

Public reporting of health care outcomes and utilization is increasingly expected by patients, purchasers, regulatory authorities, as well as physicians. Despite its clear potential to positively impact health care quality improvement efforts, most reporting standards and guidance focus on primary...

SF
TU

Predicting Overall Survival for Patients After Radiosurgery for Brain Metastases

February 3, 2014
Stereotactic & Functional, Tumor
By: 
Gavin P. Dunn, MD PhD
Gabriel Zada, MD
Source: 
Journal of Neurosurgery

Difficulties in predicting survival for brain metastasis patients is underappreciated and has ramifications for cost-effective care. Kondziolka et al. assessed the ability of clinicians to predict survival in 150 cancer patients undergoing stereotactic radiosurgery for brain metastases from 2009-11. Clinicians...

SF
TU

Resection Bed Radiosurgery Improves Local Control for Brain Metastases

February 3, 2014
Stereotactic & Functional, Tumor
By: 
Jonathan Sherman, MD
J. Bradley Elder, MD
Source: 
http://journals.lww.com/neurosurgery/Abstract/2013/12000/Predicting_Tumor_Contro...

Current management of brain metastases frequently involves stereotactic radiosurgery (SRS) and/or whole brain radiation therapy (WBRT) after surgery. This study examines factors associated with SRS to the surgical bed after brain metastasis resection. Overall, 86% of 120 patients achieved local...

TU

Dose-Dense Temozolomide Is Not Superior to Standard Dose Temozolomide for Glioblastoma

January 2, 2014
Tumor
By: 
Clark C. Chen, MD PhD
Source: 
PubMed

Escalating temozolomide dose regimen beyond that used in standard therapy, termed the dose dense regimen, has been proposed as a means to functional deplete MGMT and improve temozolomide efficacy in the management of glioblastoma. This randomized control trial evaluated 883...

ARUBA Trial: Greater Early Risk With Interventional Management of Unruptured AVM Than With Observation Alone

January 2, 2014
By: 
Alexander A. Khalessi, MD
Source: 
PubMed

The ARUBA Trial randomized patients with unruptured arteriovenous malformations (AVM) to medical management versus multi-modal therapy. As published in the Lancet, the Data Safety and Monitoring Board (DSMB) prematurely halted the trial at 223 patients (55% enrollment) due to inferior...

Pages